BRPI0514126A - derivados de naftiridina 2,8-dissubstituìdos - Google Patents
derivados de naftiridina 2,8-dissubstituìdosInfo
- Publication number
- BRPI0514126A BRPI0514126A BRPI0514126-5A BRPI0514126A BRPI0514126A BR PI0514126 A BRPI0514126 A BR PI0514126A BR PI0514126 A BRPI0514126 A BR PI0514126A BR PI0514126 A BRPI0514126 A BR PI0514126A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- disubstituted
- naphthyridine derivatives
- formula
- relates
- Prior art date
Links
- -1 2,8-disubstituted naphthyridine Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DERIVADOS DE NAFTIRIDINA 2,8-DISSUBSTITUìDOS. A invenção refere-se a compostos da fórmula A: e sais farmaceuticamente aceitáveis dos mesmos, onde R~ 1~, R~ 2~, R~ 2<39>~ R~ 3~, R~ 21~, A~ 1~, A~ 2~, X e Z são conforme aqui definido. Compostos da fórmula A são úteis no tratamento de doenças e/ou condições relacionadas à diferenciação celular, tal coma câncer, inflamação, artrite, angiogênese ou similar. A invenção também refere-se a composições farmacêuticas compreendendo compostos da invenção e métodos de tratamento das condições acima mencionadas usando tais compostos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59851804P | 2004-08-03 | 2004-08-03 | |
| PCT/US2005/027764 WO2006017672A2 (en) | 2004-08-03 | 2005-08-03 | 2, 8-disubstituted naphthyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0514126A true BRPI0514126A (pt) | 2008-05-27 |
Family
ID=35457226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514126-5A BRPI0514126A (pt) | 2004-08-03 | 2005-08-03 | derivados de naftiridina 2,8-dissubstituìdos |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7282506B2 (pt) |
| EP (1) | EP1773834A2 (pt) |
| JP (1) | JP2008509151A (pt) |
| BR (1) | BRPI0514126A (pt) |
| CA (1) | CA2575571A1 (pt) |
| MX (1) | MX2007001267A (pt) |
| WO (1) | WO2006017672A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080176A1 (es) * | 2006-03-31 | 2008-04-25 | Glaxo Group Ltd | Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs) |
| WO2008074068A1 (en) * | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Substituted quinoline derivatives as antiamyloidogeneic agents |
| US8258301B2 (en) * | 2007-05-15 | 2012-09-04 | Boehringer Ingelheim International Gmbh | Urotensin II receptor antagonists |
| CN102325754B (zh) * | 2009-01-19 | 2014-03-12 | 第一三共株式会社 | 含杂原子的环状化合物 |
| AU2010221417A1 (en) * | 2009-03-02 | 2011-09-22 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
| KR20120006016A (ko) * | 2009-04-06 | 2012-01-17 | 다이이찌 산쿄 가부시키가이샤 | 치환 페닐기를 갖는 고리형 화합물 |
| CN104812387A (zh) * | 2012-11-20 | 2015-07-29 | 霍夫曼-拉罗奇有限公司 | 取代的1,6-萘啶 |
| MX2016006052A (es) * | 2013-11-12 | 2016-07-18 | Hoffmann La Roche | Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos. |
| JP2017522324A (ja) * | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| EP3256217A1 (en) * | 2015-02-11 | 2017-12-20 | Basilea Pharmaceutica International AG | Substituted mono- and polyazanaphthalene derivatives and their use |
| CN117800969B (zh) * | 2023-09-19 | 2024-11-29 | 武汉厚先生物医药有限公司 | 肿瘤坏死因子受体复合物抑制剂及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945431A (en) * | 1996-03-15 | 1999-08-31 | Biochem Therapeutics Incorporated | Cytomegalovirus inhibiting compounds |
| CN1283995A (zh) * | 1997-12-11 | 2001-02-14 | 生化制药有限公司 | 抗病毒化合物 |
| AU2002218902A1 (en) * | 2000-12-27 | 2002-07-08 | Shire Biochem Inc. | Macrocyclic anti-viral compounds |
-
2005
- 2005-08-03 US US11/196,532 patent/US7282506B2/en not_active Expired - Fee Related
- 2005-08-03 WO PCT/US2005/027764 patent/WO2006017672A2/en not_active Ceased
- 2005-08-03 MX MX2007001267A patent/MX2007001267A/es not_active Application Discontinuation
- 2005-08-03 JP JP2007524997A patent/JP2008509151A/ja active Pending
- 2005-08-03 BR BRPI0514126-5A patent/BRPI0514126A/pt not_active IP Right Cessation
- 2005-08-03 EP EP05782681A patent/EP1773834A2/en not_active Withdrawn
- 2005-08-03 CA CA002575571A patent/CA2575571A1/en not_active Abandoned
-
2007
- 2007-10-15 US US11/872,471 patent/US20080032991A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2575571A1 (en) | 2006-02-16 |
| EP1773834A2 (en) | 2007-04-18 |
| WO2006017672A3 (en) | 2006-07-06 |
| MX2007001267A (es) | 2007-07-11 |
| US7282506B2 (en) | 2007-10-16 |
| US20060030584A1 (en) | 2006-02-09 |
| US20080032991A1 (en) | 2008-02-07 |
| JP2008509151A (ja) | 2008-03-27 |
| WO2006017672A2 (en) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607739A2 (pt) | derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado | |
| BRPI0511512A (pt) | derivados pirrolpirimidina úteis no tratamento do cáncer | |
| BR9916930A (pt) | Compostos heterocìclicos aromáticos comoagentes antiinflamatórios | |
| NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
| DE60003863D1 (de) | Dioxocyclopentylhydroxamsäure | |
| EA200971104A1 (ru) | Производные бензимидазола | |
| PL1682138T6 (pl) | Heterocykliczne inhibitory MEK | |
| NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
| BRPI0515500A (pt) | derivados piridazina para inibição de estearoil-coa-desaturase | |
| EA200501009A1 (ru) | Замещённые пирролопиразольные производные в качестве ингибиторов киназы | |
| NO20062335L (no) | Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer | |
| BR0005633A (pt) | Derivados de quinolina úteis para inibição da farnesil proteìna transferase | |
| ATE365742T1 (de) | 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren | |
| NO20063928L (no) | Substituerte kinolinforbindelser | |
| NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
| NO20045679L (no) | Nye fysiologik aktive substanser | |
| BRPI0514126A (pt) | derivados de naftiridina 2,8-dissubstituìdos | |
| ATE428422T1 (de) | Piperidin-derivate als ccr3-antagonisten | |
| CY1108246T1 (el) | ΠΑΡΑΓΩΓΑ 1Η-ΘΕΙΕΝΟ[2,3-c] ΠΥΡΑΖΟΛΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ | |
| SE0302116D0 (sv) | Novel compounds | |
| BR0313385A (pt) | Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz | |
| EA200400086A1 (ru) | Новые производные оксазолидинонов в качестве антибактериальных агентов | |
| NO20054340L (no) | Nye sammenkoplede heterocykler og deres anvendelse | |
| ATE365735T1 (de) | Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel | |
| NO20052182L (no) | Nye forbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |